Clinical Trial Update: Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pembrolizumab with chemotherapy as neoadjuvant treatment for triple-negative breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Triple Negative Breast Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2019-10-24